{"disease":{"id":"iga-nephropathy","name":"iga nephropathy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT03929887","title":"KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT04858724","title":"The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT05190848","title":"Correlation of Microbiome and Metabonomics With IgA Nephropathy","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT04557462","title":"A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":540,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04578834","title":"Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":518,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06674577","title":"A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept","phase":"PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":476,"lead_sponsor_name":"Vera Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05528991","title":"Oxford Classification and Clinical Remission After Initial Treatments in Patients With IgA Nephropathy","phase":"","overall_status":"UNKNOWN","enrollment_count":474,"lead_sponsor_name":"Shenzhen Second People's Hospital","has_results":false},{"nct_id":"NCT05797610","title":"A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":428,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04573478","title":"Atrasentan in Patients With IgA Nephropathy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":404,"lead_sponsor_name":"Chinook Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05234463","title":"Study of the Link Between Complement Activation and IgA Nephropathy Severity","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"University Hospital, Strasbourg, France","has_results":false},{"nct_id":"NCT05852938","title":"A Study of Zigakibart in Adults With IgA Nephropathy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":383,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05434325","title":"TESTING -ON Post-Trial ObservatioNal Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":366,"lead_sponsor_name":"The George Institute","has_results":false},{"nct_id":"NCT03643965","title":"Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":365,"lead_sponsor_name":"Calliditas Therapeutics AB","has_results":true},{"nct_id":"NCT03608033","title":"Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":360,"lead_sponsor_name":"Omeros Corporation","has_results":true},{"nct_id":"NCT06819826","title":"A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"Biocity Biopharmaceutics Co., Ltd.","has_results":false},{"nct_id":"NCT05016323","title":"A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":316,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT06460987","title":"Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy","phase":"","overall_status":"COMPLETED","enrollment_count":245,"lead_sponsor_name":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","has_results":false},{"nct_id":"NCT07074951","title":"Tonsillectomy and Immunosuppression in Caucasian Patients With High-risk IgA-nephropathy","phase":"NA","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"St. Petersburg State Pavlov Medical University","has_results":false},{"nct_id":"NCT06393036","title":"The Effect of OSA on Severity and Prognosis of Patients With IgAN","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT06676007","title":"A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Sichuan Provincial People's Hospital","has_results":false},{"nct_id":"NCT04833374","title":"Steroids Therapy in IgA Nephropathy With Crescents","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Sixth Affiliated Hospital, Sun Yat-sen University","has_results":false},{"nct_id":"NCT06589752","title":"Replication of the NefIgArd Trial of TRF-budesonide in Primary IgAN","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT04438603","title":"The Applicaiton of Immune Repertoire in the Diagnosis and Disease Monitoring of IgA Nephropathy","phase":"","overall_status":"UNKNOWN","enrollment_count":180,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT04689074","title":"Establishment of the Human Intestinal and Salivary Microbiota Biobank - Kidney Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari","has_results":false},{"nct_id":"NCT07098897","title":"To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"The Affiliated Hospital of Xuzhou Medical University","has_results":false},{"nct_id":"NCT03488368","title":"Longterm Renal Oucomes of STOP-IgAN Trial Participants","phase":"","overall_status":"COMPLETED","enrollment_count":148,"lead_sponsor_name":"RWTH Aachen University","has_results":false},{"nct_id":"NCT07010250","title":"Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":146,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT07030894","title":"Nefecon and Ambrisentan in IgA Nephropathy","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":129,"lead_sponsor_name":"The First Hospital of Jilin University","has_results":false},{"nct_id":"NCT07052981","title":"Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":124,"lead_sponsor_name":"Guixia Ding","has_results":false},{"nct_id":"NCT06137768","title":"A Trial of HRS-5965 Tablets in Primary IgA Nephropathy","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":123,"lead_sponsor_name":"Chengdu Suncadia Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT06580288","title":"Effect of Finerenone in IgA Nephropathy","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT04541043","title":"Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":119,"lead_sponsor_name":"Calliditas Therapeutics AB","has_results":true},{"nct_id":"NCT05824390","title":"A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":116,"lead_sponsor_name":"XIEJINGYUAN","has_results":false},{"nct_id":"NCT04525729","title":"Rituximab and RASi in Patients with IgAN","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"Nan Chen,MD","has_results":false},{"nct_id":"NCT03373461","title":"Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":112,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03945318","title":"Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":103,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04573920","title":"Atrasentan in Patients With Proteinuric Glomerular Diseases","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":103,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03366337","title":"A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT07474636","title":"Efficacy and Safety Study of HS-10542 for IgA Nephropathy","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":90,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05942625","title":"A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":84,"lead_sponsor_name":"Hansoh BioMedical R&D Company","has_results":false},{"nct_id":"NCT07481084","title":"IgA Nephropathy Insights From Treatment Experience Among Patients Receiving Iptacopan and/or Atrasentan Using Primary Data Collection","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06670352","title":"Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Haisco Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT06687174","title":"Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":72,"lead_sponsor_name":"Wuhan Createrna Science and Technology Co., Ltd","has_results":false},{"nct_id":"NCT05775042","title":"Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Keymed Biosciences Co.Ltd","has_results":false},{"nct_id":"NCT03188887","title":"Treatment of IgA Nephropathy According to Renal Lesions","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05083364","title":"Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Arrowhead Pharmaceuticals","has_results":false},{"nct_id":"NCT05398510","title":"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Pharmacodynamics of SHR-2010 by Intravenously/Subcutaneously in Healthy Subject","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Guangdong Hengrui Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT03418779","title":"Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","has_results":false},{"nct_id":"NCT05065970","title":"Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"HI-Bio, A Biogen Company","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}